- Shares of Sarepta Therapeutics (SRPT -6.3%) are notably lower on the session.
- The stock traded up on Friday as the market took a decidedly negative stance on data from a trial of Prosensa (RNA -1%) and GlaxoSmithKline's (GSK -0.2%) drisapersen (an eteplirsen competitor).
- Today's weakness in SRPT shares may be attributable to a note from Cowen which suggests the drisapersen data highlights the debate regarding dystrophin as a surrogate endpoint.
- The drisapersen data "underscores [the] point that no correlation can be drawn currently between dystrophin and clinical benefit," Cowen says.
- Adam Feuerstein's take: "SRPT bears sticking to script. We knew they'd link poor drisapersen dystrophin data to eteplirsen."
- Note: Cowen is still "bullish on SRPT shares."
Sarepta Therapeutics slides on dystrophin/ clinical benefit questions
Aug 19 2013, 11:56 ET